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Abstract: Objective: To test the immunohistochemical staining pattern of some mismatch repair (MMR) system 
proteins in endometriotic tissue (ET) and eutopic endometrium. Methods: This was a retrospective study conducted 
at the Pathology and Obstetrics and Gynecology Departments of the Udine University Hospital. We analyzed 528 
samples obtained from 246 patients affected by endometriosis and 71 samples from 71 patients with normal en-
dometrium. A tissue microarray model was used to analyze the immunohistochemical expression of MMR system 
proteins. Results: Significant loss of MMR proteins was found in the stromal component of ETs. We found MSH2 to 
be expressed at a higher level than any other MMR system proteins in eutopic endometrium and ETs, to be signifi-
cantly correlated to Ki-67 expression in both stromal and glandular components of ETs, and to be expressed at a 
significantly higher level in ETs than in eutopic endometrium. When considering the subgroup of endometriosis with 
high recurrence rate and glandular cytoplasmic staining for aurora A kinase, we found MMR proteins expressed at a 
significantly higher level in these ETs than in other ETs and eutopic endometrium of unaffected women. Conclusions: 
We found significant loss of MMR proteins (known to be associated with microsatellite instability) in the stromal 
component of ETs. The group of ETs with glandular cytoplasmic staining for aurora A kinase had higher MMR protein 
expression, suggesting an increased activity of this system. Our result suggests a novel role of increased MSH2 
expression in cellular proliferation of endometriosis. 
Keywords: Endometriosis, mismatch repair system proteins, MLH1, PMS2, MSH2, MSH6, microsatellite instability, 
aurora A kinase
Introduction
Endometriosis is a gynecological disorder, clas-
sically defined as the presence of endometrial-
like glands and stroma outside the uterus [1, 
2]. The precise etiology of endometriosis is 
unknown but some theories involving cell 
implantation or metaplasia describe the possi-
ble mechanisms of initiation of endometriotic 
lesions [3, 4]. 
Evidence in the literature suggests that oxida-
tive stress is a component of the inflammatory 
reaction associated with endometriosis and in 
the long term it can induce genetic damage, 
such as mutations to DNA single base pairs [5, 
6]. In chronically inflamed epithelium, these 
processes have been shown to lead to cancer 
development [7]. 
The DNA mismatch repair (MMR) system is 
important for promoting the genetic stability of 
eukaryotes. MMR proteins recognize and fix 
DNA single-base mismatches and small inser-
tion/deletion loops occurring during DNA repli-
cation, homologous recombination, or other 
forms of DNA damage such as oxidative stress 
[8, 9]. The MMR system is composed of differ-
ent proteins, six MutS homologues (MSH1 to 
MSH6) and four MutL homologues (MLH1, 
PMS1, PMS2, and MLH3). As part of a complex 
mechanism, MutS homologues 2 (MSH2) and 
MutS homologues 6 (MSH6) heterodimers bind 
to single base-pair mismatches. Successively, 
MutL homologues 1 (MLH1) and Post-meiotic 
segregation 2 (PMS2) heterodimers are recruit-
ed to this complex for completing the DNA 
repair process [10]. 
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One of the results of defective function of the 
MMR system is microsatellite instability (MSI). 
Microsatellites are noncoding areas of mono-
nuclear or dinuclear acid repeats, which are 
chemically unstable and prone to mutations 
[11]. MSI can be identified either using molecu-
lar diagnostics (by the resultant instability in 
length of microsatellite repeat tracts) or by 
immunohistochemical staining (for loss of mis-
match repair proteins) [12]. Both methods are 
effective and widely-accepted for identifying 
MMR defects [13]. 
Although MSI has traditionally been implicated 
in the molecular pathogenesis of epithelial cell 
carcinogenesis [5], new data suggest that such 
dysfunction is also found in mesenchymal cells 
undergoing tissue remodeling in chronic inflam-
matory disorders [11, 14]. It is now known that 
DNA alterations occur in atherosclerosis, asth-
ma, chronic obstructive pulmonary disease, 
rheumatoid arthritis, and Crohn’s disease (CD) 
[11, 15-17]. These studies hypothesized that 
the pathophysiology of the altered behavior of 
mesenchymal cells could be linked to an accu-
mulation in DNA damage, which may be directly 
related to an altered DNA-MMR function. This 
could further lead to uncontrolled cell prolifera-
tion associated with either benign pathology or, 
more drastically, neoplastic transformation. 
Few studies have linked loss of expression of 
MMR proteins and MSI in ETs with the subse-
quent development of endometriosis related 
cancer [6, 18]. 
Aurora A kinase (AAK) is an important mitotic 
regulator implicated in the assembly of the 
mitotic spindle and chromatin segregation [19]. 
Recent studies suggest that AAK is overex-
pressed in cancer and is associated with 
genomic instability [20]. In our previous publi-
cation we found high glandular cytoplasmic 
expression of AAK in a subgroup of endometri-
otic lesions with higher prevalence of relapse 
[21]. 
The main aim of our current study was to test 
the positivity of MMR system proteins in endo-
metriotic tissue (ET) and eutopic endometrium; 
further, we wanted to analyze also the immuno-
histochemical staining pattern of ET with high 
glandular cytoplasmic AAK staining. To our 
knowledge, this is the first study investigating a 
potential link between endometriosis, MMR 
proteins and AAK expression. 
Materials and methods
From the registry of the Pathology Department 
of the Udine University Hospital, a total of 277 
women who had a histopathological diagnosis 
of endometriosis between January 2000 and 
December 2010 were identified; 246 of them 
met the following inclusion criteria. We includ-
ed all Caucasian women of reproductive age at 
the time of intervention who had not taken any 
hormone therapy during the year before sur-
gery. A total of 528 paraffin blocks containing 
ET were available from these 246 women and 
we obtained for every block one core biopsy 
from formalin-fixed paraffin-embedded ET with 
representative stromal and glandular compo-
nents. The majority of the population affected 
by endometriosis and the methods used to pre-
pare our tissue microarray model (TMA) were 
the same as already described in our two previ-
ous publications, with the exception of an 
increased number of cases analysed in the cur-
rent study [21, 22]. Among the included cases 
there were neither cases with cytologic/archi-
tectural atypia of ET nor cases affected by 
known germline mutation in MMR proteins. 
Eutopic endometrial tissue was obtained from 
formalin-fixed paraffin-embedded uterine tis-
sues from all women who underwent hysterec-
tomy for leiomyomas during the period from 
2006 to 2010 and met the previously described 
inclusion criteria [21]. All Caucasian women 
with regular menses and without endometrial 
pathology, histological diagnosis of adenomyo-
sis, or use of hormonal medication during the 
year before surgery were included [21]. We 
obtained 71 endometrial core biopsies from 71 
women. According to the date of menses and 
histological confirmation based on Noyes crite-
ria [23], among these women, 29 were in the 
follicular phase (proliferative endometrium) 
and 42 in the luteal phase (secretory 
endometrium). 
The clinical and surgical data were collected as 
previously explained [21]. Staging was deter-
mined according to the American Society of 
Reproductive Medicine (ASRM) classification of 
endometriosis [24]. This study was conducted 
according to the declaration of Helsinki, follow-
ing internal review board approval. 
All immunohistochemistry stains were per-
formed on 4 µm thick sections, which were 
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tively evaluated as H-score (product of percent-
age of positive cells and intensity of staining). 
Interpretation of staining results was per-
formed as previously recommended [29, 30]. 
Data were analyzed using R (version 3.0.1) and 
P < 0.05 was considered significant. For all pro-
teins analysed the staining was investigated in 
terms of H-score or percentage of positive cells 
when Ki-67 was considered. The normality of 
variables was tested using the Kolmogorov-
Smirnov test. Non-parametric data were pre-
sented with the median value and the inter-
quartile range (IQR), whereas parametric data 
were described as the mean value and the 
standard deviation. For bivariate analysis, the 
following statistical tests were applied: the 
Wilcoxon test, T-test, and Kendall’s tau for con-
tinuous variables and the Chi-square and Fisher 
exact test for categorical variables. Because of 
the statistically significant age difference 
between cases and controls, it was necessary 
to evaluate the results by multivariate logistic 
regression analysis with age adjustment con-
sidering as dependent variable the immunohis-




Women with normal eutopic endometrium were 
older and had higher parity rates compared to 
women affected by endometriosis (P < 0.05). 
The surgical indication was in the majority of 
dewaxed in automatic PTlink station (Dako) in 
retrieval solution pH6 (S1700, Dako). 
Immunohistochemistry was preceded by a per-
oxidase blocking step [3% hydrogen peroxide 
(Sigma) for 5 min]. The sections were rinsed in 
PBS and then incubated in a wet chamber at 
4°C for 60 minutes with the following primary 
antibodies: rabbit monoclonal MLH1 (2786-1, 
Epitomics, Burlingame, CA, diluted 1:200), rab-
bit monoclonal MSH2 (2848-1, Epitomics, 
Burlingame, CA diluted 1:200), rabbit monoclo-
nal anti-Human MSH6 (AC-0047, Epitomics, 
Burlingame, CA diluted 1:200), and rabbit 
monoclonal PMS2 (2858-1, Epitomics, 
Burlingame, CA diluted 1:100) [25-28]. A Dako 
REAL™ EnVision™ Rabbit/Mouse antibody 
(Dako, K5007, Glostrup, DK) was used as sec-
ond antibody. HRP activity was detected using 
Dako REAL™ DAB+Chromogen (Dako, K5007, 
Glostrup, DK) as substrate for 3 min in accor-
dance with the manufacturer’s instructions. 
Before mounting, sections were counterstained 
with hematoxylin. The added samples were 
also stained with monoclonal Aurora A (NCL-L-
AK2, Novocastra) at a dilution of 1:50 and the 
proliferation marker Ki-67 (M7240, Dako), as 
previously described [21]. 
Microscopic analysis of the immunohistoche- 
mical staining was done by two independent 
pathologists (M.O, L.M.) as described earlier 
[21, 22]. In case of disagreement, the two pre-
vious pathologists reviewed the specimen with 
a third pathologist (C.A.B.). Lymphocyte, nor- 
mal myometrium, and tissue surrounding 
the lesions served as 
positive internal con-
trol when analyzing ML- 
H1, PMS2, MSH2, 
and MSH6 expres-
sion. Expression of 
MLH1, PMS2, MS- 
H2, and MSH6 was 
scored as negative 
when cells were neg-
ative with a positive 
internal control (0/+), 
positive when both 
lesions and internal 
control where posi-
tive (+/+) [29]. More- 
over, in the positive 
cases the staining 
was semiquantita-
Table 1. Miss-match repair proteins expression. The negative staining of at 
least one miss-match repair protein will suggest the presence of microsatel-
lite instability as previous described in the literature. The p-values reported in 
the table refers to chi-square or Fisher exact test
A. All samples
    Gland ETs (528) Proliferative E. (29) Secretory E. (42) P (*)
        ≥ 1 absent proteins of 4 14% 7% 17% NS
    Stroma
        ≥ 1 absent proteins of 4 24% 7% 19% (1)
B. Aurora A kinase glandular cytoplasm expression in ETs
    Gland ETs (29) Proliferative E. (29) Secretory E. (42) P (*)
        ≥ 1 absent proteins of 4 7% 7% 17% NS
    Stroma
        ≥ 1 absent proteins of 4 21% 7% 19% NS
(*) Significant differences (P < 0.05) between: (1) ETs and proliferative endometrium. 
NS = non significant.
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Figure 1. A: Overview of H-score values of MMR complex proteins among ETs and eutopic endometrium of unaf-
fected women. B-D: show immunostaining of MSH2 in ovarian ETs and in proliferative and secretory endometrium. 
E and F: show the correlation of Ki-67, with MSH2 considering the percentage of positive cells per slide. We found 
that cell positivity for MSH2 had a significant direct correlation with cell positivity for Ki-67 in glandular (P < 0.05) 
and stromal (P < 0.05) components of ETs. 
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cases the presence of a pelvic mass (76%, 
187/246) or of chronic pelvic disease (21%, 
52/246). The most common location of ET was 
the ovary (80%), followed by other abdomino-
pelvic locations (18%) and the bowel (2%). The 
majority of cases were affected by stage III or IV 
disease (83%, 204/246) (ASRM classification). 
The 55% of women (135/246) affected by 
endometriosis were operated during follicular 
phase and 45% (111/246) during luteal phase. 
No significant differences were found in the 
studied proteins expression between ETs 
obtained during follicular or luteal phases. 
MMR system proteins in endometriotic tissues
We analyzed our TMA model to find possible 
defects in the expression of MMR system pro-
teins and we found a significant higher preva-
lence of MMR protein loss in the stromal com-
ponent of ET than in the stroma of proliferative 
endometrium (P < 0.05, Table 1). In addition, 
the most interesting finding was that in the 
glandular and stromal components of ETs, 
MSH2 H-score values were higher than any 
other MMR system proteins (Figure 1A-D) and 
MSH2 expression correlated positively with 
Ki-67 expression ( P < 0.05, Figure 1E and 1F). 
Moreover, Ki-67 was more highly expressed in 
proliferative endometrium than in other loca-
tions ( P < 0.05) and in non-ovarian than other 
ET locations (P < 0.05). 
Table 2 reports the semiquantitative score of 
immunostaining (H-score) for the studied MMR 
system proteins. Bivariate analysis showed no 
significant differences between proliferative 
and secretory eutopic endometrium. Significant 
differences in the whole population of our TMA 
model were found among stromal and glandu-
lar MSH2 staining in bivariate and multivariate 
analysis (Table 2A). We further analyzed the 
MMR expression subdivided by ET location. 
Glandular MSH2 H-score values were higher in 
non-ovarian than in ovarian ETs and eutopic 
endometrium (Table 2C, (§§) difference n° 1, 
6, and 7). Moreover, glandular MSH2 H-score 
values were lower in proliferative endometrium 
than in ovarian and bowel ET (Table 2C, (§§) n° 
3 and 8). Meanwhile, stromal MSH2 H-score 
was higher in ovarian, non-ovarian, or bowel 
ETs than eutopic endometrium (Table 2C, (§§) 
n° 3, 4, 7, 8, and 9). Furthermore, glandular 
MLH1 H-score values were higher in non-ovari-
an ET than in other ET and eutopic endometri-
um (Table 2C, (§§) n° 1, 5, 6, and 7). Stromal 
MLH1 and PMS2 H-score values in ovarian ET 
were higher than in bowel and non-ovarian ETs 
respectively. 
MMR system protein pattern in endometriotic 
tissue expressing positive glandular cytoplas-
mic staining for AAK
Only 5.5% (29/528) of samples had glandular 
cytoplasmic expression of AAK with a median 
H-score of 35 (10-50). Among these samples 
expressing glandular cytoplasmic AAK we 
found higher expression of Ki-67, glandular and 
stromal expression of MSH6 and MSH2, and 
glandular expression of MLH1 and PMS2 than 
samples non-expressing glandular cytoplasmic 
AAK (Table 3 and Figure 2). Table 2B shows the 
analysis of H-score values of MMR proteins in 
ET specimens with glandular cytoplasmic 
expression of AAK and normal endometrium. 
MLH1 values in the glandular component of ETs 
were expressed at higher levels than in eutopic 
endometrium; however the difference was sig-
nificant only when compared to secretory endo-
metrium. MSH2 glandular and stromal staining 
values were significantly higher in ETs than in 
proliferative and secretory endometrium. PMS2 
values in the glandular component of ETs were 
expressed at a higher level than in eutopic 
endometrium, but the difference was statisti-
cally significant only when in comparison to pro-
liferative endometrium (Table 2B). Furthermore, 
among the considered ET locations in this sub-
group expressing AAK, no significant differenc-
es in MMR protein expression were found. 
Discussion
In this study we found significant loss of MMR 
protein expression in the stromal component of 
ETs. Despite this, we discovered MSH2 to be 
significantly correlated with Ki-67 expression in 
both stromal and glandular components of ETs 
and to be expressed at a significantly higher 
level in ETs than in eutopic endometrium. When 
analyzing only ET specimens staining positively 
for glandular cytoplasmic expression of AAK, 
we found MMR proteins to be expressed at sig-
nificantly higher levels compared to other ETs 
and eutopic endometrium. 
To our knowledge, there is only one other study 
in the literature investigating the role of MMR 
proteins in ET. Fuseya et al. found MSH2 and 
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Table 2. H-score values of miss-match repair proteins immunostaining among ETs and eutopic endometrium of unaffected women. (A) All popu-
lation (immunostaining among all ETs and eutopic endometrium of unaffected women); (B) Only aurora A kinase glandular cytoplasm expression 
endometriosis (immunostaining among all ET expressing aurora A kinase and eutopic endometrium of unaffected women); (C) All population (im-
munostaining among different ET locations and eutopic endometrium of unaffected women)
A ETs (528 specimens) Proliferative E. (29) Secretory E. (42) P (*) P (**)
MLH1 gland 70 (20-120) 50 (15-85) 60 (20-85) NS NS
MLH1 stroma 50 (10-100) 40 (10-60) 40 (10-68) NS NS
MSH6 gland 40 (10-90) 50 (30-105) 25 (0-90) NS NS
MSH6 stroma 20 (5-58) 20 (8-55) 10 (0-30) NS NS
MSH2 gland 210 (120-270) 140 (40-180) 100 (20-270) (1, 2) (1, 2)
MSH2 stroma 180 (120-240) 140 (40-180) 100 (30-180) (1, 2) (1, 2)
PMS2 gland 30 (20-60) 30 (20-30) 30 (20-58) NS NS
PMS2 stroma 20 (10-30) 20 (10-30) 10 (10-30) NS NS
B ETs (29) Proliferative E. (29) Secretory E. (42) p (*) p (**)
MLH1 gland 80 (52.5-155) 50 (15-85) 60 (20-85) (2) (2)
MLH1 stroma 50 (10-120) 40 (10-60) 40 (10-68) NS NS
MSH6 gland 50 (20-80) 50 (30-105) 25 (0-90) NS NS
MSH6 stroma 20 (5-60) 20 (8-55) 10 (0-30) NS NS
MSH2 gland 180 (140-270) 140 (40-180) 100 (20-270) (1, 2) (1, 2)
MSH2 stroma 180 (140-240) 140 (40-180) 100 (30-180) (1, 2) (1, 2)
PMS2 gland 50 (30-60) 30 (20-30) 30 (20-58) (1) (1)
PMS2 stroma 20 (10-40) 20 (10-30) 10 (10-30) NS
C Ovarian ETs (421) Non-ovarian ETs (94) Bowel ETs (13) Proliferative E. (29) Secretory E. (42) P (§) P (§§)
MLH1 gland 60 (15-120) 80 (50-120) 25 (1-80) 50 (15-85) 60 (20-85) (1, 5, 6, 7) (1, 5, 6, 7)
MLH1 stroma 50 (10-120) 40 (10-80) 10 (1-25) 40 (10-60) 40 (10-68) (2, 5, 8) (2)
MSH6 gland 40 (10-90) 50 (20-98) 70 (0-120) 50 (30-105) 25 (0-90) NS NS
MSH6 stroma 20 (5-60) 10 (5-40) 5 (0-20) 20 (8-55) 10 (0-30) NS NS
MSH2 gland 180 (120-270) 270 (170-270) 270 (180-270) 140 (40-180) 100 (20-270) (1, 3, 4, 6, 7, 8, 9) (1, 3, 6, 7, 8)
MSH2 stroma 180 (120-240) 160 (115-210) 240 (120-270) 140 (40-180) 100 (30-180) (3, 4, 7, 8, 9) (3, 4, 7, 8, 9)
PMS2 gland 30 (15-50) 40 (20-60) 40 (10-60) 30 (20-30) 30 (20-58) (6) NS
PMS2 stroma 20 (10-35) 10 (10-20) 0 (0-10) 20 (10-30) 10 (10-30) (1, 2, 5, 6, 8, 9) (1)
The p-value refers to Wilcoxon test (median and interquartile range) (§ or *) and multivariate logistic regression with woman age correction (§§ or **). (* or **) Significant differ-
ences (P < 0.05) between: (1) ETs and proliferative endometrium; (2) ETs and secretory endometrium; and (3) proliferative and secretory endometrium. (§ or §§) significant differ-
ences (P < 0.05) between: (1) ovarian and non-ovarian ETs; (2) ovarian and bowel ETs; (3) ovarian ETs and proliferative endometrium; (4) Ovarian ETs and secretory endometrium; 
(5) non-ovarian and bowel ETs; (6) non-ovarian ETs and proliferative endometrium; (7) non-ovarian ETs and secretory endometrium; (8) bowel ETs and proliferative endometrium; (9) 
bowel ETs and secretory endometrium; (10) proliferative and secretory endometrium. NS = non significant.
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um. These results are in contrast with pre- 
vious literature; this could be due to other stud-
ies having smaller sample sizes and consider-
ing less than four immunohistochemical 
markers. 
Recently, Fuseya et al found immunohisto-
chemical expression of MLH1 and MSH2 to 
decrease and MSI to respectively increase 
stepwise in ovarian ETs, ovarian carcinoma 
accompanied by endometriosis, and solitary 
ovarian carcinoma [6]. Moreover, they found 
increased MSI in endometriosis compared to 
eutopic endometrium, suggesting that inflam-
mation in endometriosis induces MMR abnor-
malities, leading to the malignant transforma-
tion of ovarian endometriosis [6].
In our previous publication we showed a higher 
recurrence rate in endometriotic lesions with 
high cytoplasmic expression of AAK [21]. In this 
current study, when analyzing only this sub-
group of ET specimens, overexpression of sev-
eral MMR proteins was found in comparison to 
eutopic endometrium. Glandular and stromal 
staining of MSH2 and glandular staining of 
MLH1 and PMS2 were expressed at a higher 
level in ETs than in eutopic endometrium. 
Furthermore, we found in this subgroup of 
patients with endometriosis a higher expres-
sion of MLH1, MSH6, MSH2, and PMS2 than in 
other patients affected by endometriosis. 
Patients with biochemical recurrence after rad-
ical prostatectomy for prostate cancer had sig-
nificantly higher levels of PMS2 than patients 
MLH1 to be significantly more expressed in nor-
mal endometrium than ovarian ET; they also 
noted these values to be significantly higher in 
proliferative than in secretory eutopic endome-
trium [6]. We found no significant differences 
between proliferative and secretory endometri-
um and, in contrast with previous findings; we 
observed significantly higher MSH2 levels in 
ovarian ET compared to normal endometrium. 
Our study also included information on addi-
tional MMR proteins (MSH6 and PMS2) in dif-
ferent ET locations -ovarian, non-ovarian and 
bowel- and in stromal and glandular compo-
nents of ET and eutopic endometrium. Finally, 
in contrast with our results, Fuseya et al. found 
a significant correlation between MLH1 and 
MSH2 proteins and Ki-67 expression only in 
eutopic endometrium and not in ET [6]. 
Loss of MMR protein expression is known to be 
associated with MSI. Fuseya et al. demonstrat-
ed a significant correlation between loss of 
MMR protein expression and MSI in ET [6]. In 
our study, we looked for the absence of any of 
the studied MMR system proteins among 
ET locations and eutopic endometrium. Con- 
sidering the low incidence of ovarian cancer 
(3.1% of female cancers in our region) and the 
young mean age of our patients with endome-
triosis (39 years old), no cases of cancers were 
identified in our sample. 
We found a prevalence of MMR protein expres-
sion loss of 7% (gland) and 7% (stroma) in pro-
liferative endometrium, 17% (gland) and 19% 
(stroma) in secretory endome-
trium, and 14% (gland) and 
24% (stroma) in ETs (Table 1). 
Studies in the literature report 
0% MSI in normal endometri-
um, 5% in hyperplastic endo-
metrium [6, 31], 15% in endo-
metriosis and 30% in ovarian 
cancer [6]. When further ana-
lyzing our results, loss of MMR 
protein expression in stromal 
endometriosis (24%) was sig-
nificantly higher than in the 
stroma of proliferative endo-
metrium (7%) (P < 0.05, Table 
1). Moreover, we noticed an 
unexpected high prevalence 
of MMR protein expression 
loss in secretory endometri-
Table 3. Woman’s age and expression of studied proteins between 
samples expressing or not glandular cytoplasmic aurora A kinase 
(AAK). The p-value refers to Wilcoxon test
Samples non-express 






Woman’s age (years) 38 (31-46) 39 (33-47) 0.301
MLH1 gland (H-score) 60 (10-120) 80 (52-155) < 0.05
MLH1 stroma (H-score) 50 (10-100) 50 (10-120) 0.838
MSH6 gland (H-score) 20 (5-60) 50 (20-80) < 0.05
MSH6 stroma (H-score) 10 (0-40) 20 (5-60) < 0.05
MSH2 gland (H-score) 160 (90-240) 180 (140-270) 0.079
MSH2 stroma (H-score) 140 (90-210) 180 (140-240) < 0.05
PMS2 gland (H-score) 30 (10-60) 50 (30-60) < 0.05
PMS2 stroma (H-score) 20 (10-30) 20 (10-40) 0.643
Ki-67 positivity (%) 0 (0-3) 3 (1-6) < 0.05
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Moreover, it is known that in ETs the oxidative 
environment, characteristic of the inflammato-
ry reaction, promotes cellular proliferation [36]. 
In our study we found MSH2 positivity to be sig-
Figure 2. A: H-score values of MMR complex proteins in a selected sub-gruop 
of ETs expressing aurora A kinase at higher levels than eutopic endometrium. 
B-G: show immunostaining of MLH1, MSH2, and PMS2 in ovarian ETs and 
in proliferative endometrium among a selected sub-gruop of ETs expressing 
high glandular cytoplasmic aurora A kinase.
with no recurrences [32]. Moreover, high MLH1-
expression has been proposed as a marker for 
the prediction of high risk of distant metasta-
ses in colon cancer [33]. 
The exact role of MMR pro-
tein elevation is still specula-
tive but may involve aberrant 
and improper binding of 
these proteins, leading to 
inactivation of the MMR sys-
tem [34]. This could result 
from uncommon mutations in 
the MMR system not leading 
to an alteration of protein 
expression, but of protein 
function [33]. In addition to 
elevated AAK values, as pre-
viously discovered in our 
study [21], MMR protein ele-
vation may be a predictor of 
biochemical recurrence of 
endometriotic lesions follow-
ing surgery. This finding may 
identify a potential new mark-
er for recurrent endometrio-
sis and uncover a potentially 
novel pathway for targeted 
therapeutics. 
In our analysis we demon-
strated that MSH2 H-score 
values in glandular and stro-
mal components of ETs were 
higher than any other MMR 
proteins. In addition, MSH2 
was significantly correlated to 
ki-67 and was significantly 
more expressed in ETs than 
eutopic endometrium sug-
gesting a possible role of 
MSH2 in endometriosis prolif-
eration. In support of this 
hypothesis, newer literature 
suggests that chronic inflam-
mation may alter the MMR 
system [6, 11, 14]. Using 
immunohistochemistry, Floer 
and colleagues demonstrat-
ed an isolated increased 
expression of MSH2, but no 
MSI, in tissues and myofibro-
blasts affected by CD [11]. In 
fact, MSH2 modulates both 
cell cycle regulation and 
apoptosis [35]. 
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nificantly correlated to Ki-67 positivity in both 
stromal and glandular components of ETs. Also 
in CD affected specimens, increased expres-
sion of MSH2 was associated with increased 
cell proliferation [11]. These similar results let 
us assume a role of MSH2 alike that hypothe-
sized for CD. In the presence of oxidative stress, 
MSH2 could play a role in promoting cellular 
proliferation. 
This is the first study demonstrating increased 
expression of MSH2 and a positive correlation 
between MSH2 and Ki-67 levels in endometri-
otic lesions. Increased expression of MSH2 in 
endometriotic cells appeared to be linked to 
their increased proliferative capacity, propos-
ing a new pathophysiological mechanism 
underlying cell proliferation and scar formation 
in ETs. 
Conclusions
Despite two weaknesses -the retrospective 
nature of the study and the use of immunohis-
tochemical analysis alone- a major strength of 
this study is the great number of cases ana-
lyzed. Our purposes, hypothesis and conclu-
sions were based on data obtained from this 
TMA study; future in vitro and in vivo studies are 
planned to validate our hypothesis. 
In our study, we found loss of expression of 
MMR proteins in the stromal component of ETs, 
using immunohistochemistry. The group of ETs 
with glandular cytoplasmic staining for AAK, 
previously shown to be associated with higher 
recurrence rates [21], had higher MMR protein 
expression suggesting an increased activity of 
this system in the subset of endometriotic 
lesions with high recurrence rate. Furthermore, 
higher MSH2 expression in ETs than in eutopic 
endometrium suggests a novel function of 
MSH2 in promoting cellular proliferation in the 
presence of oxidative stress.
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